SPOTLIGHT: ImaRx switches development focus


It's the season for strategic alternatives in biotechnology. This time it's ImaRx Therapeutics' turn, which has changed its focus from developing its SonoLysis program--proprietary microbubbles and ultrasound to treat ischemic stroke--to concentrating on the commercial opportunities for urokinase product sales. In a release, the company explained that they would have needed to find new financing this year if they had stayed focused on the clinical development of SonoLysis. Now those charges could be borne by a "third party" drawn in by the strategic review. Release

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.